LONDON: GSK’s new CEO Luke Miels said today that the drugmaker will aim to lift sales growth and speed up work on new medicines in its next phase of growth through a sharper focus on programmes that ...

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms ...

GSK said today it had agreed a deal worth up to $750m to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences ...

BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place ...

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

Bengaluru: GSK said on Tuesday it had agreed a deal worth up to USD 750 million to buy a trispecific T cell-engager (TCE), a ...

(Alliance News) - GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday.

LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker will aim to lift sales growth and speed up work on new medicines in its next ‌phase of growth through a sharper ...